Biogen (BIIB) Change in Accured Expenses (2009 - 2026)

Biogen (BIIB) has reported Change in Accured Expenses for 18 consecutive years, with -$243.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Change in Accured Expenses rose 19.07% year-over-year to -$243.2 million; the TTM figure through Mar 2026 stood at -$190.7 million (up 36.88% YoY), while the FY2025 annual figure was -$248.0 million, down 38.78% from the prior year.
• Change in Accured Expenses came in at -$243.2 million for Q1 2026 at Biogen, down from -$215.3 million in the prior quarter.
• The five-year high for Change in Accured Expenses was $1.1 billion in Q2 2022, with the low at -$745.7 million in Q4 2022.
• Average Change in Accured Expenses over 5 years is -$57.9 million, with a median of -$94.5 million recorded in 2024.
• Across the five-year window, Change in Accured Expenses sank 854.76% in 2022 and jumped 24864.71% in 2023, its largest moves.
• Year by year, Change in Accured Expenses stood at -$745.7 million in 2022, then jumped by 33.55% to -$495.5 million in 2023, then surged by 80.93% to -$94.5 million in 2024, then slumped by 127.83% to -$215.3 million in 2025, then decreased by 12.96% to -$243.2 million in 2026.
• According to Business Quant data, Change in Accured Expenses over the past three periods registered -$243.2 million, -$215.3 million, and $286.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.